Insmed Inc

1INSM

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    1,271

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,365.7024.700.30%
CAC 407,593.8738.000.50%
DAX 4022,496.9871.150.32%
Dow JONES (US)40,669.36141.740.35%
FTSE 1008,492.342.51-0.03%
HKSE22,119.41111.300.51%
NASDAQ17,446.3414.98-0.09%
Nikkei 22536,452.30406.921.13%
NZX 50 Index12,148.60245.292.06%
S&P 5005,569.068.230.15%
S&P/ASX 2008,145.6019.400.24%
SSE Composite Index3,279.037.62-0.23%

Market Movers